20/20 Biolabs, Inc. (AIDX)
0.5139
-0.04
(-7.29%)
USD |
NASDAQ |
Aug 24, 16:00
0.5139
0.00 (0.00%)
After-Hours: 20:00
20/20 Biolabs Debt to Equity Ratio : 0.1812 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.1812 |
| March 31, 2026 | 0.3357 |
| December 31, 2025 | -70.76 |
| September 30, 2025 | 10.69 |
| March 31, 2025 |
| Date | Value |
|---|---|
| December 31, 2024 | 0.5473 |
| September 30, 2024 | |
| June 30, 2023 | 0.1998 |
| March 31, 2023 | 0.1677 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Sanara MedTech, Inc. | 6.109 |
| Intelligent Bio Solutions, Inc. | 0.3301 |
| Anteris Technologies Global Corp. | 0.0132 |
| Quest Diagnostics, Inc. | 0.8493 |
| Labcorp Holdings, Inc. | 0.7861 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 6.123M |
| Total Liabilities (Quarterly) | 2.964M |
| Shareholders Equity (Quarterly) | 3.159M |
| Current Ratio | 1.990 |
| Net Debt Paydown Yield | 0.79% |